

Definition, etiopathogenesis, clinical manifestations, nonpharmacological and pharmacological management of the diseases associated with Respiratory System

Asthma

Definition:

- Asthma is a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and airway inflammation, leading to episodes of wheezing, breathlessness, chest tightness, and coughing.

Etiopathogenesis:

- Asthma results from a complex interaction of **genetic** and **environmental** factors that cause:
 - Airway inflammation
 - Bronchial hyperresponsiveness
 - Mucus hypersecretion
 - Airflow obstruction (reversible)

Triggering factors:

1. **Allergens** (dust mites, pollen, pet dander)
2. **Respiratory infections**
3. **Cold air, exercise**
4. **Air pollutants and smoke**
5. **Drugs** (NSAIDs, β -blockers)
6. **Occupational irritants**
7. **Genetic predisposition** (e.g., family history of atopy or asthma)

Immunological Mechanisms:

- Activation of **TH2 helper cells** → production of **IL-4, IL-5, IL-13**
- **Eosinophilic inflammation** of airways
- **Mast cell degranulation** → histamine release → bronchoconstriction

Clinical Manifestations:

- Wheezing (especially during expiration)
- Shortness of breath

- Chest tightness
- Cough (often worse at night or early morning)
- Prolonged expiration
- Use of accessory muscles during breathing
- Tachypnea, tachycardia

Severe or life-threatening asthma:

- Inability to speak in full sentences
- Silent chest (no wheeze due to no airflow)
- Cyanosis
- Decreased oxygen saturation

Nonpharmacological Management:

- Allergen avoidance (dust, smoke, pollen, pets)
- Avoidance of cold air or irritants
- Proper inhaler technique education
- Smoking cessation
- Vaccinations (Influenza, Pneumococcal)
- Pulmonary rehabilitation
- Weight loss and exercise (if obesity is a factor)

Pharmacological Management:

1. Reliever Medications (for acute symptoms):

- **Short-acting β 2-agonists (SABA):** Salbutamol (albuterol)
- **Anticholinergics:** Ipratropium (less common in asthma)

2. Controller Medications (for long-term control):

- **Inhaled corticosteroids (ICS):** Beclomethasone, Budesonide, Fluticasone (mainstay)
- **Long-acting β 2-agonists (LABA):** Salmeterol, Formoterol (always combined with ICS)
- **Leukotriene receptor antagonists (LTRA):** Montelukast, Zafirlukast
- **Theophylline** (used less commonly due to narrow therapeutic index)
- **Biologics** (for severe asthma):
 - **Omalizumab** (anti-IgE)

- Mepolizumab, Benralizumab (anti-IL-5)

Chronic Obstructive Pulmonary Disease (COPD)

Definition:

- COPD is a progressive, irreversible, obstructive lung disease characterized by persistent airflow limitation, typically caused by chronic bronchitis and/or emphysema, associated with an abnormal inflammatory response to noxious particles or gases, especially cigarette smoke.

Etiopathogenesis:

- Cigarette smoking is the most important cause
- Air pollutants, occupational dust/fumes
- Genetic factors (e.g., α -1 antitrypsin deficiency)
- Frequent respiratory infections
- Aging

Pathophysiology:

- Chronic exposure to irritants → **inflammation** of airways → **mucus hypersecretion**
- **Loss of alveolar walls** (emphysema) → decreased gas exchange
- Airway narrowing and fibrosis
- Air trapping and hyperinflation
- Increased breathing work

Clinical Manifestations:

Chronic bronchitis phenotype:

- Productive cough for at least 3 months in 2 consecutive years
- Dyspnea on exertion
- Cyanosis ("blue bloaters")

Emphysema phenotype:

- Dyspnea, minimal cough
- Hyperinflated chest ("barrel chest")
- Pursed-lip breathing
- Weight loss

- "Pink puffers"

Exacerbations are common and may be triggered by infections.

Nonpharmacological Management:

- **Smoking cessation** – most important intervention
- **Pulmonary rehabilitation**
- **Vaccination:** Influenza, Pneumococcal
- **Nutritional support**
- **Oxygen therapy** (for $\text{PaO}_2 < 55$ mmHg or $\text{SaO}_2 < 88\%$)
- **Breathing techniques:** Pursed-lip breathing, diaphragmatic breathing

Pharmacological Management:

Bronchodilators:

- **Short-acting β_2 -agonists (SABA):** Salbutamol
- **Long-acting β_2 -agonists (LABA):** Salmeterol, Formoterol
- **Anticholinergics:**
 - **Short-acting (SAMA):** Ipratropium
 - **Long-acting (LAMA):** Tiotropium

Inhaled corticosteroids (ICS):

- Less effective than in asthma
- Used in combination with LABA or LAMA in moderate-to-severe cases

Other agents:

- **PDE-4 inhibitors:** Roflumilast (reduces exacerbations)
- **Theophylline**
- **Antibiotics:** Used during exacerbations (e.g., azithromycin)



FREE PREVIEW

[Click here to visit our website](#)

PHARMACY PREMIUM NOTES

Complete subject
and semesters are
available on
FirstHope app only.



[Scan or click here](#)

Click here to get the app



Available on Google Play

JOIN THE FIRSTHOPE COMMUNITY

Join our Telegram channel

Click here to join Telegram



[Scan or click here](#)

@FirstHopeNotes

Instagram

@firsthope.official

[Click here to follow >](#)

YouTube channel

FirstHope-Pharmacy / Live streams

[Click here to watch >](#)

WhatsApp channel

Follow FirstHope on WhatsApp

[Click here to join >](#)

FirstHope website

firsthopenotes.com

[Click here to visit >](#)

B.Pharm / D.Pharm / M.Pharm / Pharm.D

Preview notes. Complete subjects and semesters in the FirstHope app.